7,528.25

-46.00

-0.61%

52,401.00

-97.00

-0.18%

27,718.50

-296.00

-1.06%

Russell 2000 Futures

2,821.70

-27.00

-0.95%

4.9520

+0.0880

+1.81%

21.23

+1.31

+6.59%

4,066.20

-48.30

-1.17%

73,866.75

-920.75

-1.23%

Crude Oil Dec 26

84.62

-2.23

-2.57%

US Private Equity

10,850.15

0.00

0.00%

LSE - Delayed Quote GBp

GSK plc (GSK.L)

1,938.50 +34.00 (+1.79%)

As of 1:57:04 PM GMT. Market Open.

Loading Chart for GSK.L

Chart Range Bar

Interval:

In partnership with ChartIQ

What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders

What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders

Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?

Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?

GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

Vocabria + Rekambys associated with greater adherence versus daily oral therapy in a US real-world study, as ViiV Healthcare presents broader long-acting portfolio and pipeline data at HIV Glasgow

Vocabria + Rekambys associated with greater adherence versus daily oral therapy in a US real-world study, as ViiV Healthcare presents broader long-acting portfolio and pipeline data at HIV Glasgow

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?

Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder

GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Mobilize your Website

View Site in Mobile | Classic

Share by: